History only #

232 medicines have figures that stop before the ranking window opens, so they appear nowhere else on this page - not ranked, not part-year, and not in the table above, which needs a quarter inside the window. Absence meant two different things and a reader could not tell them apart, so the reason is stated per row. "Company stopped naming it" means the sponsor still reports other medicines in the window and no longer breaks this one out. "Not covered here" means we have no recent figures for that company at all, which is a gap in this page rather than anything the company did.

Medicines whose reported figures end before the ranking window
Drug Company Why it is not ranked Last reported EURm, that quarter
Paxlovid Pfizer Company stopped naming it 2024Q1 1,874
OFEV Boehringer Not covered here 2023Q2 735
Polio / Pertussis / Hib Sanofi Company stopped naming it 2024Q1 636
Cimzia UCB Not covered here 2023Q4 522
Humalog Eli Lilly Company stopped naming it 2024Q1 496
Repatha Amgen Company stopped naming it 2024Q1 476
Ingrezza Neurocrine Biosciences Not covered here 2024Q1 466
Vyvgart argenx Not covered here 2024Q1 366
Yescarta Gilead Company stopped naming it 2024Q1 350
Kyprolis Amgen Company stopped naming it 2024Q1 346
Lagevrio Merck Company stopped naming it 2024Q1 322
Betmiga Astellas Company stopped naming it 2024Q1 304
Mirena Bayer Not covered here 2024Q1 293
Meningitis+ Sanofi Company stopped naming it 2024Q1 286
Nubeqa Bayer Not covered here 2024Q1 283
Austedo Teva Not covered here 2024Q1 260
Adempas Bayer + Merck Company stopped naming it 2024Q1 236
Janumet Merck Company stopped naming it 2024Q1 231
Cyramza Eli Lilly Company stopped naming it 2024Q1 212
Emgality Eli Lilly Company stopped naming it 2024Q1 208
Vaxneuvance Merck Company stopped naming it 2024Q1 202
Olumiant Eli Lilly Company stopped naming it 2024Q1 200
RotaTeq Merck Company stopped naming it 2024Q1 199
Humulin Eli Lilly Company stopped naming it 2024Q1 190
Mvasi Amgen Company stopped naming it 2024Q1 186
Zithromax Pfizer Company stopped naming it 2024Q1 184
Epidioelex Jazz Company stopped naming it 2024Q1 183
Kogenate/Kovaltry Bayer Not covered here 2024Q1 171
Infanrix GSK Company stopped naming it 2024Q1 169
Keppra UCB Not covered here 2023Q1 167
Zytiga J&J Company stopped naming it 2024Q1 167
Yasminelle Bayer Not covered here 2024Q1 165
Rexulti Lundbeck Not covered here 2023Q4 163
Amgevita Amgen Company stopped naming it 2024Q1 155
Sulperazon Pfizer Company stopped naming it 2024Q1 154
Aspirin Cardio Bayer Not covered here 2024Q1 151
Brintellix Lundbeck Not covered here 2023Q4 150
Vimpat UCB Not covered here 2023Q1 149
Inflectra Pfizer Company stopped naming it 2024Q1 146
Basaglar Eli Lilly Company stopped naming it 2024Q1 145
Briviact UCB Not covered here 2023Q1 138
Bosulif Pfizer Company stopped naming it 2024Q1 134
Erbitux Eli Lilly Company stopped naming it 2024Q1 133
AmBisome Gilead Company stopped naming it 2024Q1 133
Adalat Bayer Not covered here 2023Q4 128
Exondys Sarepta Not covered here 2023Q1 124
Ozurdex AbbVie Company stopped naming it 2024Q1 121
Gleevec Novartis Company stopped naming it 2023Q4 119
Stivarga Bayer Not covered here 2023Q4 119
Ultravist Bayer Not covered here 2023Q4 116
Zavicefta Pfizer Company stopped naming it 2024Q1 115
Genotropin Pfizer Company stopped naming it 2024Q1 110
Gadovist Bayer Not covered here 2023Q4 110
Risperdal J&J Company stopped naming it 2022Q4 110
Abilify Maintena Lundbeck Not covered here 2023Q4 109
Neulasta Amgen Company stopped naming it 2024Q1 109
Braftovi Pfizer Company stopped naming it 2024Q1 107
Duodopa AbbVie Company stopped naming it 2024Q1 106
Tamiflu Roche Company stopped naming it 2025Q1 106
Tyvyt Eli Lilly Company stopped naming it 2023Q4 106
Kalydeco Vertex Company stopped naming it 2023Q3 104
Isentress Merck Company stopped naming it 2024Q1 102
Gilenya Novartis Company stopped naming it 2024Q4 102
Xeloda Roche Company stopped naming it 2016Q1 101
Mayzent Novartis Company stopped naming it 2023Q4 99
Tukysa Pfizer Company stopped naming it 2024Q1 98
Parsabiv Amgen Company stopped naming it 2024Q1 97
Ultibro Novartis Company stopped naming it 2023Q3 96
Trajenta Eli Lilly Company stopped naming it 2023Q4 95
Procrit/Eprex J&J Company stopped naming it 2021Q3 95
BeneFIX Pfizer Company stopped naming it 2024Q1 95
Rylaze Jazz Company stopped naming it 2023Q4 95
Premarin Pfizer Company stopped naming it 2023Q4 91
Priorix GSK Company stopped naming it 2024Q1 91
Afinitor/Votubia Novartis Company stopped naming it 2023Q4 90
Invokana J&J Company stopped naming it 2022Q4 89
Voltaren/Cataflam Novartis Company stopped naming it 2022Q3 85
Kerendia Bayer Not covered here 2023Q4 85
Xalkori Pfizer Company stopped naming it 2023Q4 85
Avodart GSK Company stopped naming it 2023Q4 84
Lumigan/Ganfort AbbVie Company stopped naming it 2024Q1 84
Ruxience Pfizer Company stopped naming it 2023Q4 82
Zirabev Pfizer Company stopped naming it 2023Q4 82
Ravicti Amgen Company stopped naming it 2023Q2 81
Neupro UCB Not covered here 2023Q1 80
Oxbryta Pfizer Company stopped naming it 2024Q1 77
Lumakras Amgen Company stopped naming it 2024Q1 76
Zortress/Certican Novartis Company stopped naming it 2022Q3 76
Letairis Gilead Company stopped naming it 2024Q1 74
Uplizna Amgen Company stopped naming it 2024Q1 74
Faslodex AstraZeneca Company stopped naming it 2023Q4 74
Retacrit Pfizer Company stopped naming it 2023Q4 74
Neoral/Sandimmun(e) Novartis Company stopped naming it 2022Q3 74
Cialis Eli Lilly Company stopped naming it 2023Q4 73
Influenza vaccines Sanofi Company stopped naming it 2024Q1 73
Copaxone Teva Not covered here 2023Q4 73
Votrient Novartis Company stopped naming it 2023Q4 72
Evrenzo AstraZeneca Company stopped naming it 2024Q1 71
Medrol Pfizer Company stopped naming it 2023Q4 71
Aromasin Pfizer Company stopped naming it 2023Q4 71
Norditropin Novo Nordisk Company stopped naming it 2023Q3 71
Retevmo Eli Lilly Company stopped naming it 2023Q4 68
Dificid Merck Company stopped naming it 2024Q1 67
Vyepti Lundbeck Not covered here 2023Q4 66
Ebglyss Eli Lilly Company stopped naming it 2023Q4 63
Aptiom Sumitomo Not covered here 2022Q4 62
Somavert Pfizer Company stopped naming it 2023Q4 62
Bespona Pfizer Company stopped naming it 2023Q4 60
Xiidra Novartis Company stopped naming it 2023Q3 59
Ajovy Teva Not covered here 2023Q4 59
Fragmin Pfizer Company stopped naming it 2023Q4 59
Cipralex Lundbeck Not covered here 2023Q4 58
Avamys/Veramyst GSK Company stopped naming it 2023Q4 56
Forteo Eli Lilly Company stopped naming it 2024Q1 56
Yupeiri Viatris Company stopped naming it 2023Q4 56
Pneumovax23 Merck Company stopped naming it 2024Q1 56
Kanuma AstraZeneca Company stopped naming it 2024Q4 56
Andexxa AstraZeneca Company stopped naming it 2024Q4 55
Alphagan/Combigan AbbVie Company stopped naming it 2024Q1 54
Nimenrix Pfizer Company stopped naming it 2023Q4 54
Cymbalta Eli Lilly Company stopped naming it 2023Q4 53
NeoRecormon/Epogin Roche Company stopped naming it 2024Q1 53
Restasis AbbVie Company stopped naming it 2024Q1 52
Eloxatine Sanofi Company stopped naming it 2020Q4 52
Noxafil Merck Company stopped naming it 2024Q1 52
Zerbaxa Merck Company stopped naming it 2024Q1 52
Delstrigo Merck Company stopped naming it 2024Q1 52
Influvac Viatris Company stopped naming it 2023Q4 51
Bendeka/Treanda Teva Not covered here 2023Q4 49
Defitelio Jazz Company stopped naming it 2023Q4 48
NovoEight Novo Nordisk Company stopped naming it 2020Q4 47
Incruse Ellipta GSK Company stopped naming it 2023Q4 46
Renagel/Renvela Sanofi Company stopped naming it 2020Q4 44
Onglyza AstraZeneca Company stopped naming it 2023Q4 44
Onureg BMS Company stopped naming it 2023Q4 44
Beovu Novartis Company stopped naming it 2023Q3 43
Belsomra Merck Company stopped naming it 2024Q1 42
Adakveo Novartis Company stopped naming it 2023Q4 42
Alimta Eli Lilly Company stopped naming it 2023Q4 42
Orgovyx Sumitomo Not covered here 2022Q4 42
Orkambi Vertex Company stopped naming it 2023Q4 41
Taxotere Sanofi Company stopped naming it 2020Q4 41
Sutent Pfizer Company stopped naming it 2023Q4 41
Tavneos Amgen Company stopped naming it 2023Q4 41
Gemtesa Sumitomo Not covered here 2022Q4 41
Zyprexa Eli Lilly Company stopped naming it 2023Q4 41
Kanjinti Amgen Company stopped naming it 2023Q4 39
Pifeltro Merck Company stopped naming it 2024Q1 39
Cibinqo Pfizer Company stopped naming it 2024Q1 39
Tabrecta Novartis Company stopped naming it 2023Q4 38
Epogen Amgen Company stopped naming it 2024Q1 38
Bydureon AstraZeneca Company stopped naming it 2023Q4 36
Primaxin Merck Company stopped naming it 2023Q4 36
Neupogen Amgen Company stopped naming it 2022Q4 33
Xanax Viatris Company stopped naming it 2023Q4 33
Jaypirca Eli Lilly Company stopped naming it 2023Q4 30
Latuda Sumitomo Not covered here 2023Q3 29
Symdeko/Symkevi Vertex Company stopped naming it 2023Q2 29
Vaqta Merck Company stopped naming it 2023Q4 27
Inrecbib BMS Company stopped naming it 2023Q4 27
Tivdak Eli Lilly + Pfizer Company stopped naming it 2024Q1 26
Humatrope Eli Lilly Company stopped naming it 2023Q4 25
Epkinly AbbVie + Genmab Company stopped naming it 2024Q1 25
Iressa AstraZeneca Company stopped naming it 2022Q4 24
Jcovden J&J Company stopped naming it 2024Q1 23
Vesicare Astellas Company stopped naming it 2023Q3 23
Complera/Eviplera Gilead Company stopped naming it 2023Q4 22
Enjaymo* Sanofi Company stopped naming it 2024Q4 22
Fampyra Biogen Company stopped naming it 2023Q4 21
Elunate Eli Lilly Company stopped naming it 2023Q4 21
Talzenna Pfizer Company stopped naming it 2024Q1 21
Stribild Gilead Company stopped naming it 2023Q4 20
Viread Gilead Company stopped naming it 2023Q4 20
Recombinate Takeda Company stopped naming it 2025Q1 19
Pemazyre Incyte Company stopped naming it 2023Q4 19
Baqsimi Eli Lilly Company stopped naming it 2023Q4 18
Inrebic Not stated Not covered here 2021Q4 18
Truvada Gilead Company stopped naming it 2023Q4 17
Trumenba Pfizer Company stopped naming it 2023Q4 16
Casodex AstraZeneca Company stopped naming it 2022Q4 16
Fluarix GSK Company stopped naming it 2024Q1 15
Bevespi AstraZeneca Company stopped naming it 2023Q4 14
Arimidex AstraZeneca Company stopped naming it 2022Q4 14
Xevudy GSK Company stopped naming it 2024Q4 13
Daliresp/Daxas AstraZeneca Company stopped naming it 2023Q4 12
Arnuity Ellipta GSK Company stopped naming it 2023Q4 12
Orpathys AstraZeneca Company stopped naming it 2024Q4 9
Velcade J&J + Takeda Company stopped naming it 2024Q1 9
Byooviz Biogen Company stopped naming it 2023Q4 9
Minjuvi Incyte Company stopped naming it 2023Q4 8
Omvoh Eli Lilly Company stopped naming it 2023Q4 8
Reyvow Eli Lilly Company stopped naming it 2023Q4 7
Sensipar Amgen Company stopped naming it 2022Q4 7
Zinbryta Biogen Company stopped naming it 2022Q3 6
Alofisel Takeda Company stopped naming it 2024Q1 6
Fumaderm Biogen Company stopped naming it 2022Q4 2
Arcalyst Regeneron Company stopped naming it 2020Q2 2
Inmazeb Regeneron Company stopped naming it 2024Q1 1
Augtyro BMS Company stopped naming it 2023Q4 1
Exkivity Takeda Company stopped naming it 2024Q1 1
Ronapreve Regeneron + Roche Company stopped naming it 2024Q1 0
Aduhelm Biogen Company stopped naming it 2022Q4 0
Harvoni Gilead Company stopped naming it 2024Q1 0
Vaxzevria AstraZeneca Company stopped naming it 2024Q1 0
Zetia Merck Company stopped naming it 2023Q3 0
Ellipta products GSK Company stopped naming it 2022Q1 0
Evusheld AstraZeneca Company stopped naming it 2023Q3 0
COVID19 antibodies Eli Lilly Company stopped naming it 2024Q1 0
Esbriet Roche Company stopped naming it 2024Q1 0
Zepatier Merck Company stopped naming it 2023Q3 0
Baraclude BMS Company stopped naming it 2023Q4 0
Atripla Gilead Company stopped naming it 2023Q3 0
Chantix/Champix Pfizer Company stopped naming it 2023Q4 0
Tarceva Roche Company stopped naming it 2024Q1 0
Singulair Merck Company stopped naming it 2023Q3 0
Lupron AbbVie Company stopped naming it 2023Q4 0
Implanon Merck Company stopped naming it 2023Q3 0
Synthroid AbbVie Company stopped naming it 2023Q4 0
Vidaza BMS Company stopped naming it 2023Q4 0
Cancidas Merck Company stopped naming it 2023Q3 0
Arcoxia Merck Company stopped naming it 2023Q3 0
Atozet Merck Company stopped naming it 2023Q3 0
Vosevi Gilead Company stopped naming it 2021Q3 0
Empliciti BMS Company stopped naming it 2023Q4 0
Kaletra AbbVie Company stopped naming it 2023Q4 0
Orilissa AbbVie Company stopped naming it 2023Q4 0
Lemtrada Sanofi Company stopped naming it 2023Q4 0
Rocephin Roche Company stopped naming it 2024Q1 0
Exjade Novartis Company stopped naming it 2023Q3 0
Vytorin Merck Company stopped naming it 2023Q3 0
Nexplanon Merck Company stopped naming it 2023Q3 0
Jynarque Otsuka Not covered here 2023Q2 0

Quarters reported below zero #

10 sponsor-quarters on this board are negative. They are real and disclosed, not errors: a rebate, returns or price-concession true-up can exceed the quarter's own sales and land as contra-revenue. The largest by an order of magnitude is Pfizer's reversal on the US government Paxlovid exchange programme. They are listed because a reader charting one of these series sees a bar below the axis with nothing to explain it, and deleting them would silently overstate the year they fall in.

Sponsor-quarters reported as negative figures
Drug Company Quarter EURm
Paxlovid Pfizer 2023Q4 -2,917
Victoza Novo Nordisk 2024Q3 -43
Vaxzevria AstraZeneca 2023Q4 -16
Cervarix GSK 2025Q3 -13
Blenrep GSK 2024Q2 -2
Intuniv Takeda 2023Q1 -2
Orpathys AstraZeneca 2022Q4 -1
FluMist AstraZeneca 2022Q1 -1
Exkivity Takeda 2023Q4 -1
Vaxchora Bavarian Nordic 2024Q4 -0

Top drugs by revenue #

The medicines earning the most right now, ranked on the four most recent quarters each company has reported, converted to euros at the average rate over each quarter. A trailing year rather than a calendar one, so the board does not spend most of its life describing a year that ended long ago. Every row carries its quarterly history: hover a drug to see it, or tap on a phone. For what regulators have decided rather than what medicines earn, see drug approvals and EU decisions.

Ranked on 2025Q3-2026Q2. Quarterly series 2010Q1-2026Q2. This ranks what these medicines earned, not what they are worth taking - nothing here is medical advice, and nothing here is a recommendation to buy or sell a share. Spotted a wrong number? Tell us.

337
drugs ranked
EUR 610.5bn
combined revenue
29
companies
38
drug classes
13
therapeutic areas

Filters #

Pick any combination. Within a facet, chips are OR'd; across facets they are AND'd. State is saved in the URL hash so a filtered view is shareable.

of 337 drugs shown

The board #

Click any column header to sort. Select a drug for its quarterly series - the panel names its specific drug class, which the Area column summarises. A figure marked ≥ is at least that much: a drug two companies both sell where only one of them has reported for part of the window. A figure marked group is a franchise line rather than one medicine, carried because the company stopped naming the brands under it and this is now the only figure it publishes. Drugs selling for less than a full year are in their own table below - their totals are real, but a rank would put them in a comparison they are not in.

# Drug Company Area EURm, 12m YoY Trend
1 MounjaroTirzepatide Eli Lilly Metabolic 27,898 +94.1%
2 KeytrudaPembrolizumab Merck Cancer & immune 27,689 -1.0%
3 DupixentDupilumab Sanofi Dermatology 17,726 +24.4%
4 SkyriziRisankizumab AbbVie Cancer & immune 16,898 +24.1%
5 OzempicSemaglutide Novo Nordisk Metabolic 16,303 -5.1%
6 ZepboundTirzepatide Eli Lilly Metabolic 14,526 +79.1%
7 EliquisApixaban BMS + Pfizer Blood 13,562≥ +9.7%
8 DarzalexDaratumumab J&J Cancer & immune 13,503 +14.1%
9 BiktarvyBictegravir / Emtricitabine / Tenofovir alafenamide Gilead Anti-infectives 12,682 -0.9%
10 WegovySemaglutide Novo Nordisk Metabolic 10,703 +7.8%
11 TrikaftaElexacaftor / tezacaftor / ivacaftor Vertex Respiratory 8,642 -9.6%
12 OpdivoNivolumab BMS Cancer & immune 8,452 -4.8%
13 RinvoqUpadacitinib AbbVie Cancer & immune 7,892 +19.4%
14 OcrevusOcrelizumab Roche Cancer & immune 7,537 +3.1%
15 FarxigaDapagliflozin AstraZeneca Metabolic 7,024 -5.6%
16 TagrissoOsimertinib AstraZeneca Cancer & immune 6,466 +2.5%
17 ImfinziDurvalumab AstraZeneca Cancer & immune 5,914 +24.5%
18 CosentyxSecukinumab Novartis Cancer & immune 5,913 -0.3%
19 TremfyaGuselkumab J&J Cancer & immune 5,718 +52.1%
20 VyndaqelTafamidis Pfizer Nervous system 5,697 +1.7%
21 XtandiEnzalutamide Astellas + Pfizer Cancer & immune 5,577≥ -1.5%
22 PrevnarPneumococcal conjugate vaccine Pfizer Anti-infectives 5,553 -5.8%
23 EntyvioVedolizumab Takeda Cancer & immune 5,523 -1.5%
24 HemlibraEmicizumab Roche Blood 5,216 +2.8%
25 KisqaliRibociclib Novartis Cancer & immune 5,026 +43.3%
26 VerzenioAbemaciclib Eli Lilly Cancer & immune 5,018 -2.0%
27 XolairOmalizumab Novartis + Roche Respiratory 4,902 +7.6%
28 EntrestoSacubitril / Valsartan Novartis Cardiovascular 4,814 -39.6%
29 Immunoglobulin Takeda - 4,500group -2.4%
30 VabysmoFaricimab Roche Eye & ear 4,425 +0.8%
31 ImbruvicaIbrutinib AbbVie + J&J Cancer & immune 4,376 -22.0%
32 UltomirisRavulizumab AstraZeneca Cancer & immune 4,351 +8.9%
33 KesimptaOfatumuumab Novartis Cancer & immune 4,321 +25.0%
34 ShingrixZoster vaccine GSK Anti-infectives 4,316 +9.7%
35 GardasilGardasil Merck Anti-infectives 4,302 -25.9%
36 TecentriqAtezolizumab Roche Cancer & immune 3,821 +0.8%
37 TrulicityDulaglutide Eli Lilly Metabolic 3,625 -16.9%
38 StelaraUstekinumab J&J Cancer & immune 3,598 -52.9%
39 IbrancePalbociclib Pfizer Cancer & immune 3,569 -7.7%
40 Botox TherapeuticBotulinum toxin AbbVie Musculoskeletal 3,452 +6.9%
41 Invega SustennaPaliperidone J&J Nervous system 3,403 -7.6%
42 VraylarCariprazine AbbVie Nervous system 3,372 +6.0%
43 ComirnatyTozinameran / BNT162b2 BioNTech + Pfizer Anti-infectives 3,359 -37.0%
44 Trelegy ElliptaFluticasone furoate / umeclidinium bromide / vilanterol GSK Respiratory 3,334 +0.9%
45 DovatoDolutegravir / lamivudine GSK Anti-infectives 3,300 +14.1%
46 ErleadaApalutamide J&J Cancer & immune 3,292 +10.2%
47 CalquenceAcalabrutinib AstraZeneca Cancer & immune 3,283 +9.8%
48 OrenciaAbatacept BMS Cancer & immune 3,280 -2.7%
49 PadcevEnfortumab vedotin Astellas + Pfizer Cancer & immune 3,246 +16.6%
50 HumiraAdalimumab AbbVie Cancer & immune 3,159 -44.7%
51 ProliaDenosumab Amgen Musculoskeletal 3,155 -22.6%
52 TaltzIxekizumab Eli Lilly Cancer & immune 3,038 -4.0%
53 PerjetaPertuzumab Roche Cancer & immune 2,966 -15.5%
54 Amvuttra Alnylam Nervous system 2,928 +137.6%
55 LynparzaOlaparib AstraZeneca + Merck Cancer & immune 2,851≥ -18.3%
56 DescovyTenofovir alafenamide Gilead Anti-infectives 2,825 +25.9%
57 EnhertuTrastuzumab deruxtecan AstraZeneca Cancer & immune 2,771 +30.5%
58 PhesgoPertuzumab / trastuzumab / hyaluronidase Roche Cancer & immune 2,769 +22.0%
59 RybelsusSemaglutide Novo Nordisk Metabolic 2,751 -13.5%
60 Jakafi / JakaviRuxolitinib Incyte Cancer & immune 2,739 -0.3%
61 TezspireTezepelumab Amgen + AstraZeneca Respiratory 2,591 +35.7%
62 VenclextaVenetoclax AbbVie Cancer & immune 2,553 +3.3%
63 YervoyIpilimumab BMS Cancer & immune 2,546 +3.8%
64 NucalaMepolizumab GSK Respiratory 2,486 +11.7%
65 SymbicortBudesonide / formoterol AstraZeneca Respiratory 2,456 -5.6%
66 ActemraTocilizumab Roche Cancer & immune 2,447 -12.9%
67 Beyfortus AstraZeneca + Sanofi Anti-infectives 2,383 -10.2%
68 Botox Cosmetic AbbVie - 2,358 -1.4%
69 SimponiGolimumab J&J + Merck Cancer & immune 2,216≥ -1.6%
70 ReblozylLuspatercept BMS + Merck Blood 2,205≥ +17.7%
71 BenlystaBelimumab GSK Cancer & immune 2,123 +10.0%
72 PluvictoLutetium (177Lu) vipivotide tetraxetan Novartis Various 2,111 +47.3%
73 ProQuad / VariVaxMMRV vaccine Merck Anti-infectives 2,086 -7.1%
74 OpsumitMacitentan J&J Cardiovascular 2,083 +2.3%
75 EvenityRomosozumab Amgen Musculoskeletal 2,072 +26.1%
76 KadcylaTrastuzumab emtansine Roche Cancer & immune 2,057 -4.8%
77 EvrysdiRisdiplam Roche Musculoskeletal 2,006 +13.8%
78 CarvyktiCiltacabtagene autoleucel J&J Cancer & immune 2,001 +52.6%
79 JakaviRuxolitinib Novartis Cancer & immune 1,910 +3.7%
80 Tafinlar + MekinistDabrafenib Novartis Cancer & immune 1,856 -7.6%
81 OtezlaApremilast Amgen Cancer & immune 1,828 -11.2%
82 CabenuvaCabotegravir / rilpivirine GSK Anti-infectives 1,827 +29.1%
83 FasenraBenralizumab AstraZeneca Respiratory 1,812 +8.0%
84 Pomalyst / ImnovidPomalidomide BMS Cancer & immune 1,786 -37.1%
85 TepezzaTeprotumumab Amgen Cancer & immune 1,786 +6.2%
86 SpikevaxElasomeran / mRNA-1273 Moderna Anti-infectives 1,756 -34.8%
87 SpravatoEsketamine J&J Nervous system 1,727 +43.2%
88 EnbrelEtanercept Amgen + Pfizer Cancer & immune 1,726≥ -36.5%
89 IlarisCanakinumab Novartis Cancer & immune 1,726 +11.7%
90 StrensiqAsfotase alfa AstraZeneca Metabolic 1,701 +22.5%
91 AlecensaAlectinib Roche Cancer & immune 1,681 +0.0%
92 UptraviSelexipag J&J Blood 1,674 -1.6%
93 PolivyPolatuzumab vedotin Roche Cancer & immune 1,674 +17.9%
94 RevlimidLenalidomide BMS Cancer & immune 1,673 -59.9%
95 LantusInsulin glargine Sanofi Metabolic 1,670 -4.4%
96 Winrevair Merck Cardiovascular 1,664 +87.9%
97 BridionSugammadex Merck Various 1,636 +0.5%
98 XywavCalcium, magnesium, potassium, and sodium oxybates Jazz Nervous system 1,523 +7.0%
99 TivicayDolutegravir GSK Anti-infectives 1,502 -4.8%
100 XgevaDenosumab Amgen Musculoskeletal 1,500 -25.9%
101 Scemblix Novartis Cancer & immune 1,496 +76.3%
102 TysabriNatalizumab Biogen Cancer & immune 1,476 -3.0%
103 CabometyxCabozantinib Exelixis + Takeda Cancer & immune 1,470≥ +3.0%
104 BlincytoBlinatumomab Amgen Cancer & immune 1,451 +7.9%
105 LipitorAtorvastatin Viatris Cardiovascular 1,447 +4.4%
106 NplateRomiplostim Amgen Blood 1,444 +6.7%
107 Breyanzi BMS Cancer & immune 1,412 +40.7%
108 SolirisEculizumab AstraZeneca Cancer & immune 1,407 -27.8%
109 BexseroMeningococcal vaccine GSK Anti-infectives 1,394 +7.2%
110 Alyftrek Vertex Respiratory 1,394 -
111 ToujeoInsulin glargine Sanofi Metabolic 1,382 +7.5%
112 RemicadeInfliximab J&J + Merck Cancer & immune 1,377≥ -11.9%
113 TrodelvySacituzumab govitecan Gilead Cancer & immune 1,372 +11.2%
114 Prezista / Prezcobix / Rezolsta / SymtuzaDarunavir J&J Anti-infectives 1,368 -10.2%
115 NurtecRimegepant Pfizer Nervous system 1,364 +11.2%
116 LeqvioInclisiran Novartis Cardiovascular 1,351 +50.7%
117 MabThera + RituxanRituximab Roche Cancer & immune 1,329 -3.9%
118 EdurantRilpivirine J&J Anti-infectives 1,309 +3.9%
119 Altuviiio Sanofi - 1,292 +36.9%
120 SpinrazaNusinersen Biogen Musculoskeletal 1,292 -13.4%
121 TakhzyroLanadelumab Takeda Blood 1,272 -6.9%
122 UbrelvyUbrogepant AbbVie Nervous system 1,221 +15.8%
123 KrystexxaPegloticase Amgen Musculoskeletal 1,210 +6.3%
124 Activase / TNKaseTenecteplase / Alteplase Roche Blood 1,202 -2.3%
125 PrografTacrolimus Astellas Cancer & immune 1,194 -2.1%
126 VectibixPanitumumab Amgen + Takeda Cancer & immune 1,190 +1.4%
127 Camzyos BMS Cardiovascular 1,183 +61.8%
128 Betanis / Myrbetriq / Betmiga Astellas - 1,163 +13.2%
129 AranespDarbepoetin alfa Amgen Blood 1,160 -6.0%
130 Breztri AstraZeneca Respiratory 1,128 +10.9%
131 GenvoyaTenofovir alafenamide Gilead Anti-infectives 1,124 -26.4%
132 JanuviaSitagliptin Merck Metabolic 1,122 -15.0%
133 Jemperli GSK Cancer & immune 1,117 +44.7%
134 OpdualagNivolumab / Relatlimab BMS Cancer & immune 1,109 +18.0%
135 VyvanseLisdexamfetamine Takeda Nervous system 1,108 -38.6%
136 MavyretGlecaprevir / Pibrentasvir AbbVie Anti-infectives 1,099 -6.0%
137 ZolgensmaOnasemnogene abeparvovec Novartis Musculoskeletal 1,094 -0.5%
138 Relvar / Breo ElliptaFluticasone furoate / vilanterol GSK Respiratory 1,089 -12.7%
139 CrestorRosuvastatin AstraZeneca Cardiovascular 1,088 -1.5%
140 GazyvaObinutuzumab Roche Cancer & immune 1,064 +5.0%
141 Qulipta AbbVie Nervous system 1,048 +36.6%
142 Lorbrena Pfizer Cancer & immune 1,037 +29.5%
143 ZoladexGoserelin AstraZeneca Cancer & immune 1,023 -0.4%
144 FabrazymeAlpha-galactosidase Sanofi Metabolic 1,017 -2.9%
145 SandostatinOctreotide Novartis Hormones 1,014 -10.5%
146 TriumeqAbacavir / dolutegravir / lamivudine GSK Anti-infectives 1,013 -26.3%
147 HerceptinTrastuzumab Roche Cancer & immune 1,005 -21.1%
148 EpclusaSofosbuvir / Velpatasvir Gilead Anti-infectives 1,004 -22.2%
149 AbrysvoRSV vaccine Pfizer Anti-infectives 984 +29.5%
150 Epidiolex Epidyolex Jazz - 970 +6.0%
151 Caplyta J&J - 961 -
152 PrevymisLetermovir Merck Anti-infectives 951 +20.5%
153 Seretide / AdvairFluticasone / salmeterol GSK Respiratory 949 -10.7%
154 VemlidyTenofovir alafenamide Gilead Anti-infectives 937 +2.3%
155 AvastinBevacizumab Roche Cancer & immune 934 -20.0%
156 LinzessLinaclotide AbbVie Metabolic 925 +15.7%
157 LenvimaLenvatinib Merck Cancer & immune 917 -3.1%
158 XeljanzTofacitinib Pfizer Cancer & immune 916 -10.7%
159 OdefseyTenofovir alafenamide Gilead Anti-infectives 898 -21.3%
160 PlavixClopidogrel Sanofi Blood 877 -4.0%
161 Other Neuroscience J&J - 853 -14.3%
162 Opzelura Incyte Dermatology 848 +58.2%
163 GattexTeduglutide Takeda Metabolic 845 -4.6%
164 Juvederm AbbVie - 840 -11.2%
165 Nexviazyme Sanofi Metabolic 829 +12.9%
166 Voxzogo BioMarin Musculoskeletal 827 +7.9%
167 Rybrevant + Lazcluze J&J - 823 +69.0%
168 PraluentAlirocumab Regeneron + Sanofi Cardiovascular 817 +13.2%
169 Promacta / RevoladeEltrombopag Novartis Blood 815 -59.7%
170 Elevidys Sarepta + Roche Musculoskeletal 815 -50.5%
171 ArexvyRespiratory syncytial virus vaccine GSK Anti-infectives 812 +39.3%
172 TakecabVonoprazan Takeda Metabolic 811 -0.5%
173 Albumin Takeda - 792group -10.6%
174 BoostrixDPT vaccine GSK Anti-infectives 774 -4.6%
175 InlytaAxitinib Pfizer Cancer & immune 766 -12.4%
176 Welireg Merck Cancer & immune 760 +38.3%
177 JulucaDolutegravir / rilpivirine GSK Anti-infectives 755 -5.1%
178 LovenoxEnoxaparin sodium Sanofi Blood 739 -18.9%
179 Truqap AstraZeneca Cancer & immune 735 +35.7%
180 OjjaaraMomelotinib GSK Cancer & immune 731 +31.8%
181 LutatheraDOTA-TATE Novartis Various 731 +1.9%
182 Capvaxive Merck - 728 +138.7%
183 TrintellixVortioxetine Takeda Nervous system 725 -3.9%
184 VentolinSalbutamol GSK Respiratory 720 -13.2%
185 Tecvayli J&J Cancer & immune 699 +27.2%
186 LeuplinLeuprorelin Takeda Cancer & immune 695 -3.4%
187 CerezymeImiglucerase Sanofi Metabolic 684 -2.0%
188 VimizimElosulfase alfa BioMarin Metabolic 680 -4.3%
189 LokelmaSodium zirconium cyclosilicate AstraZeneca Various 678 +18.8%
190 Ayvakit Sanofi Cancer & immune 672 -
191 SarclisaIsatuximab Sanofi Cancer & immune 666 +28.1%
192 VumerityDiroximel fumarate Biogen Cancer & immune 661 +5.2%
193 NorvascAmlodipine Viatris Cardiovascular 656 +3.4%
194 Saphnelo AstraZeneca Cancer & immune 654 +24.2%
195 Elahere AbbVie Cancer & immune 653 +13.4%
196 ExforgeAmlodipine / valsartan Novartis Cardiovascular 644 -0.3%
197 ZejulaNiraparib GSK + Takeda Cancer & immune 643 -16.0%
198 Novo human insulinNPH insulin Novo Nordisk Metabolic 636group -27.0%
199 Koselugo AstraZeneca Cancer & immune 629 +3.4%
200 RotarixRotavirus vaccine GSK Anti-infectives 619 -10.8%
201 Anoro ElliptaUmeclidinium bromide / vilanterol GSK Respiratory 617 -8.4%
202 Fabhalta Novartis Cancer & immune 599 +116.7%
203 TasignaNilotinib Novartis Cancer & immune 598 -57.7%
204 AvonexInterferon beta-1a Biogen Cancer & immune 587 -7.6%
205 Apretude GSK Anti-infectives 586 +43.5%
206 AlprolixFactor IX Sanofi Blood 580 -6.8%
207 AdvateFactor VIII Takeda Blood 574 -13.4%
208 KevzaraSarilumab Sanofi Cancer & immune 563 +17.3%
209 VekluryRemdesivir Gilead Anti-infectives 561 -58.1%
210 ElapraseIdursulfase Takeda Metabolic 555 -7.1%
211 IclusigPonatinib Incyte + Takeda Cancer & immune 554 +2.8%
212 Infanrix, Pediarix GSK - 552 -14.5%
213 Seloken AstraZeneca - 545 -1.2%
214 Opdivo Qvantig BMS Cancer & immune 534 -
215 DiovanValsartan Novartis Cardiovascular 523 -4.2%
216 Rezurock Sanofi Cancer & immune 523 -0.6%
217 Zeposia BMS Cancer & immune 521 +0.9%
218 Talvey J&J - 512 +58.5%
219 Skyclarys Biogen Nervous system 502 +19.0%
220 Thymoglobulin Sanofi Cancer & immune 499 +1.0%
221 FlixotideFluticasone propionate GSK Respiratory 494 -11.0%
222 Izervay Astellas Eye & ear 492 +30.5%
223 PulmozymeDornase alfa Roche Respiratory 480 -3.7%
224 ConcertaMethylphenidate J&J Nervous system 475 -15.7%
225 NinlaroIxazomib Takeda Cancer & immune 473 -12.8%
226 Priorix, Priorix Tetra, Varilrix GSK - 468 +13.4%
227 MyozymeAlglucosidase alfa Sanofi Metabolic 464 -19.3%
228 SymtuzaTenofovir alafenamide Gilead Anti-infectives 457 -4.6%
229 ReplagalAlpha-galactosidase Takeda Metabolic 455 -3.4%
230 PulmicortBudesonide AstraZeneca Respiratory 448 -14.2%
231 AldurazymeIduronidase BioMarin + Sanofi Metabolic 446 -10.1%
232 MenveoMeningococcal vaccine GSK Anti-infectives 442 -7.8%
233 LucentisRanibizumab Novartis + Roche Eye & ear 438≥ -41.7%
234 Naglazyme BioMarin Metabolic 435 -2.3%
235 XospataGilteritinib Astellas Cancer & immune 424 +1.9%
236 Aprovel Sanofi - 423 +1.9%
237 BrilintaTicagrelor AstraZeneca Blood 419 -61.8%
238 LyricaPregabalin Viatris Nervous system 418 -8.6%
239 Enspryng Roche Cancer & immune 413 +12.8%
240 TecfideraDimethyl fumarate Biogen Cancer & immune 412 -48.0%
241 CellCeptMycophenolic acid Roche Cancer & immune 406 -3.8%
242 EpiPen Viatris - 400 +1.7%
243 Palynziq BioMarin Metabolic 394 +9.8%
244 BenepaliEtanercept Biogen Cancer & immune 393 -8.4%
245 Columvi Roche Cancer & immune 390 +61.3%
246 Vyloy Astellas Cancer & immune 388 +143.6%
247 JYNNEOS / IMVANEX Bavarian Nordic - 379 -24.3%
248 Fluarix, FluLaval GSK - 365 -22.2%
249 Viagra Viatris Genito-urinary 358 +0.5%
250 Rylaze Enrylaze Jazz - 353 -2.9%
251 CerdelgaEliglustat Sanofi Metabolic 352 +5.4%
252 MadoparL-DOPA Roche Nervous system 336 -12.3%
253 Fruzaqla Takeda Cancer & immune 333 +12.1%
254 VprivVelaglucerase alfa Takeda Metabolic 326 -3.7%
255 ZepzelcaLurbinectedin Jazz Cancer & immune 323 +16.6%
256 Piqray / VijoiceAlpelisib Novartis Cancer & immune 322 -18.8%
257 Adynovate Takeda Blood 314 -16.6%
258 SoliquaInsulin glargine / lixisenatide Sanofi Metabolic 311 +24.9%
259 SprycelDasatinib BMS Cancer & immune 308 -57.3%
260 Multaq Sanofi Cardiovascular 305 -1.3%
261 KymriahTisagenlecleucel Novartis Cancer & immune 301 -20.0%
262 SaxendaLiraglutide Novo Nordisk Metabolic 295 -55.5%
263 Imjudo AstraZeneca Cancer & immune 289 +0.2%
264 Veozah Astellas Genito-urinary 288 +27.4%
265 CabliviCaplacizumab Sanofi Blood 288 +5.9%
266 Rabipur / RabAvert Bavarian Nordic - 285 +36.1%
267 EloctateAntihemophilic Factor Sanofi Blood 282 -9.6%
268 Livtencity Takeda Anti-infectives 280 +27.0%
269 GivlaariGivosiran Alnylam Metabolic 279 +7.2%
270 Sotyktu BMS Cancer & immune 276 +9.7%
271 Tecartus Gilead Cancer & immune 273 -18.9%
272 Erivedge Roche Cancer & immune 268 -6.2%
273 Intuniv Takeda Cardiovascular 263 +2.3%
274 JevtanaCabazitaxel Sanofi Cancer & immune 258 -11.0%
275 FluMist AstraZeneca - 247 -
276 PantolocPantoprazole Takeda Metabolic 247 -8.6%
277 Xenpozyme Sanofi Metabolic 245 +29.6%
278 Qdenga Takeda - 243 +13.4%
279 CelebrexCelecoxib Viatris Musculoskeletal 243 -3.8%
280 Zoloft Viatris Nervous system 238 +7.8%
281 Yupelri Viatris Respiratory 236 +1.2%
282 EffexorVenlafaxine Viatris Nervous system 226 -2.7%
283 AbraxanePaclitaxel BMS Cancer & immune 226 -61.5%
284 AlunbrigBrigatinib Takeda Cancer & immune 214 -1.2%
285 Wainua AstraZeneca Nervous system 214 +56.9%
286 Zurzuvae Biogen Nervous system 212 +95.0%
287 Dexilant Takeda Metabolic 209 -2.9%
288 PlegridyPeginterferon beta-1a Biogen Cancer & immune 207 -12.1%
289 VictozaLiraglutide Novo Nordisk Metabolic 196 -53.6%
290 Itovebi Roche Cancer & immune 196 -
291 Defitelio Defibrotide Jazz - 189 -3.2%
292 Niktimvo Incyte Cancer & immune 186 -
293 Krazati BMS Cancer & immune 184 +18.1%
294 Cobenfy BMS Nervous system 182 -
295 Feiba Takeda Blood 179 -17.1%
296 OxlumoLumasiran Alnylam Metabolic 176 +11.1%
297 LialdaMesalazine Takeda Metabolic 170 +2.8%
298 Brineura BioMarin Metabolic 168 +5.2%
299 Casgevy Vertex Blood 164 +229.5%
300 Evkeeza Regeneron Cardiovascular 162 +23.9%
301 Minjuvimonjuvi Incyte - 160 +39.5%
302 ImraldiAdalimumab Biogen Cancer & immune 157 -14.2%
303 Airsupra AstraZeneca Respiratory 157 +47.8%
304 roxadustat AstraZeneca - 155 -47.6%
305 Vonvendi Takeda - 152 +16.5%
306 Datroway AstraZeneca Cancer & immune 139 -
307 Hemofil / Immunate / Immunine Takeda - 137 -8.8%
308 Xalabrands Viatris - 136 -5.2%
309 Amitiza Viatris Metabolic 134 -5.2%
310 Adderall Xr Takeda - 132 -19.7%
311 Dymista Viatris Respiratory 128 -20.7%
312 Zynyz Incyte Cancer & immune 125 +887.9%
313 Modeyso Jazz - 118 -
314 XyremSodium oxybate Jazz Nervous system 116 -30.0%
315 Vyxeos Jazz Cancer & immune 112 -24.8%
316 Journavx Vertex - 107 -
317 Qalsody Biogen Nervous system 99 +85.8%
318 OnpattroPatisiran Alnylam Nervous system 94 -50.9%
319 Encepur Bavarian Nordic - 89 +21.9%
320 Firazyr Takeda Blood 84 -22.7%
321 Kuvan BioMarin Metabolic 82 -17.8%
322 Adzynma Takeda - 75 +45.5%
323 Cinryze Takeda Blood 72 -26.6%
324 Tzield Sanofi Metabolic 71 +14.5%
325 Eohilia Takeda - 50 +25.3%
326 Fosrenol Takeda Various 44 -17.6%
327 Ziihera Jazz Cancer & immune 39 -
328 FlixabiInfliximab Biogen Cancer & immune 38 -31.6%
329 Azilva Takeda - 36 -41.6%
330 Wayrilz Sanofi - 34 -
331 Vivotif Bavarian Nordic - 29 +21.9%
332 Penmenvy GSK - 29 -
333 Roctavian BioMarin Blood 26 -24.7%
334 Vimkunya Bavarian Nordic - 20 -
335 Qfitlia Sanofi Blood 20 -
336 mResvia Moderna - 14 -45.3%
337 Vaxchora Bavarian Nordic - 4 -40.1%

Selling, but not yet for a full year #

15 more medicines reported the latest quarter without having reported all four. Their figures are real and cover only the quarters they have - nothing is annualised - so they are listed here rather than ranked, where two quarters would sit among four as if that were like for like. Mostly launches; group marks a franchise line a company began publishing when it stopped naming the brands beneath it.

Qs Drug Company Area EURm so far YoY Trend
2/4 Fast-acting insulin Novo Nordisk - 1,157group -
2/4 Long-acting insulin Novo Nordisk - 1,157group -
2/4 Wegovy pillSemaglutide Novo Nordisk Metabolic 733 -
2/4 Premix insulin Novo Nordisk - 694group -
2/4 Myfortic Novartis Cancer & immune 185 -
2/4 ApidraInsulin glulisine Sanofi Metabolic 140 -
3/4 Rhapsido Novartis Cancer & immune 103 -
2/4 Synvisc Sanofi - 93 -
3/4 Blenrep GSK Cancer & immune 83 -
3/4 Vanrafia Novartis - 48 -
2/4 Exdensur GSK Respiratory 34 -
3/4 Cometriq Exelixis Cancer & immune 7 -
2/4 Myqorzo Sanofi - 3 -
1/4 Baxfendy AstraZeneca Cardiovascular 3 -
1/4 Etcamah AstraZeneca - 3 -

Not ranked: a seller stopped reporting #

7 medicines are sold by more than one company, and one of those companies no longer publishes its share. What is left is a real figure from the company still reporting, but it is not the worldwide total and ranking it as one would put a fraction of a drug against whole ones: Xtandi is missing roughly three quarters of itself. They are listed with the last quarter that company published and how much of the drug it was carrying at the time.

Drug Still reporting Stopped reporting Last published Their share then
Creon Viatris AbbVie 2024Q1 84%
Jardiance Eli Lilly Boehringer 2022Q1 67%
Xarelto J&J Bayer 2024Q1 66%
Aimovig Novartis Amgen 2023Q4 64%
Adcetris Takeda Pfizer 2024Q1 52%
Eylea Regeneron Bayer 2024Q1 39%
Libtayo Regeneron Sanofi 2023Q4 25%

No longer reported separately #

25 medicines were selling inside the window and then stopped appearing in their company's own figures. That is a change in what the company discloses, not a gap here and not a drug that stopped selling: Novo moved its insulins into franchise lines in 2026, so Tresiba and NovoRapid end at 2025Q4 while the franchise carries on, and GSK did the same with Augmentin, Lamictal, Cervarix and Synflorix. They are listed with the last quarter anyone published.

Drug Company Last reported EURm, that quarter
NovoRapid Novo Nordisk 2025Q4 541
Tresiba Novo Nordisk 2025Q4 408
NovoSeven Novo Nordisk 2025Q4 241
Augmentin GSK 2025Q4 180
Ryzodeg Novo Nordisk 2025Q4 174
Nexium AstraZeneca 2025Q4 166
NovoMix Novo Nordisk 2025Q4 162
Xultophy Novo Nordisk 2025Q4 155
Fiasp Novo Nordisk 2025Q4 112
Lamictal GSK 2025Q4 104
Mircera Roche 2025Q3 99
Galvus Novartis 2025Q4 98
Abecma BMS 2025Q4 86
Xofluza Roche 2025Q3 65
Synagis AstraZeneca 2025Q4 62
Rukobia GSK 2025Q4 53
Aubagio Sanofi 2025Q4 51
Levemir Novo Nordisk 2025Q4 46
Fasturtec Sanofi 2025Q4 44
Synflorix GSK 2025Q4 26
Awiqli Novo Nordisk 2025Q4 20
Resolor/Motegrity Takeda 2025Q4 12
Cervarix GSK 2025Q4 9
Mozobil Sanofi 2025Q4 6
Blujepa GSK 2026Q1 1